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NEOPLASIA
Decreased PARP and procaspase-2 protein levels are associated with cellular
drug resistance in childhood acute lymphoblastic leukemia
Amy Holleman, Monique L. den Boer, Karin M. Kazemier, H. Berna Beverloo, Anne R. M. von Bergh,
Gritta E. Janka-Schaub, and Rob Pieters
Drug resistance in childhood acute lym-
phoblastic leukemia (ALL) and acute my-
eloid leukemia (AML) is associated with
impaired ability to induce apoptosis. To
elucidate causes of apoptotic defects, we
studied the protein expression of Apaf-1,
procaspases-2, -3, -6, -7, -8, -10, and
poly(adenosine diphosphate [ADP]-ri-
bose) polymerase (PARP) in cells from
children with acute lymphoblastic leuke-
mia (ALL; n  43) and acute myeloid leu-
kemia (AML; n  10). PARP expression
was present in all B-lineage samples, but
absent in 4 of 15 T-lineage ALL samples and
3 of 10AML cases, which was not caused by
genomic deletions. PARP expression was a
median 7-fold lower in T-lineage ALL
(P < .001) and 10-fold lower in AML
(P < .001) compared with B-lineage ALL.
PARP expression was 4-fold lower in
prednisolone, vincristine and L-aspara-
ginase (PVA)–resistant compared with
PVA-sensitive ALL patients (P < .001).
Procaspase-2 expression was 3-fold
lower in T-lineage ALL (P  .022) and
AML (P  .014) compared with B-lin-
eage ALL. In addition, procaspase-2 ex-
pression was 2-fold lower in PVA-resis-
tant compared to PVA-sensitive ALL
patients (P .042). No relation between apo-
ptotic protease-activating factor 1 (Apaf-1),
procaspases-3, -6, -7, -8, -10, and drug resis-
tance was found. In conclusion, low base-
line expression of PARP and procaspase-2
is related to cellular drug resistance in child-
hood acute lymphoblastic leukemia. (Blood.
2005;106:1817-1823)
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Introduction
The treatment of pediatric acute leukemia has greatly improved in
the past 4 decades, resulting in long-term disease-free survival of
approximately 80%1 for acute lymphoblastic leukemia (ALL) and
60% for acute myeloid leukemia (AML).2 Despite this progress,
therapy resistance in a significant number of children still forms a
major obstacle to successful treatment. We and others have
previously shown that ALL patients whose leukemia cells exhibit
in vitro resistance to antileukemic agents have a significantly worse
prognosis than patients whose leukemic cells are sensitive.3-6
Compared with ALL, leukemic cells of children with AML have a
less favorable prognosis and are in vitro more resistant to several
antileukemic agents.7
Apoptosis is the predominant form of cell death triggered in
vivo and in vitro by chemotherapeutic agents in hematologic
malignancies.8 There are 2 major routes by which apoptosis can be
induced: the intrinsic and the extrinsic apoptosis pathways. The
intrinsic pathway is initiated by mitochondrial damage that leads to
release of cytochrome c from the mitochondrial intermembrane
space.9 Upon entry in the cytoplasm, cytochrome c interacts with
apoptotic protease-activating factor 1 (Apaf-1), deoxyadenosine
triphosphate (dATP), and procaspase-9 to form a complex known
as the apoptosome.10 In the apoptosome, caspase-9 is activated,
which in turn induces processing and activation of downstream
effector caspases such as caspases-2, -3, -6, and -7.11,12 Activation
of the effector caspases results in the cleavage of a number of
structural and regulatory cellular proteins (eg, poly(adenosine
diphosphate [ADP]-ribose) polymerase [PARP; also known as
PARP1 and ADPRT]) and lamins.13,14 Initiation of the extrinsic
apoptosis pathway involves ligand-induced aggregation of mem-
brane receptors of the tumor necrosis factor receptor superfamily
and subsequent cytoplasmic recruitment of Fas-associated protein
with death domain (FADD), and procaspase-8 or procaspase-10 to
form the death-inducing signaling complex (DISC).15,16 Within the
DISC procaspase-8 or procaspase-10 is activated and released back
into the cytoplasm, where it induces activation of downstream
effector caspases. Both pathways converge at the level of caspase-3
activation and therefore have several downstream effector caspases
and substrates (eg, PARP) in common.
Decreased apoptosis may be an important event in the acquisi-
tion of cellular drug resistance in pediatric acute leukemia.17
Studies evaluating the expression levels of apoptotic proteins in
clinical samples are limited in leukemia and mainly restricted to
adult acute leukemia.18-22 In the present study, we examined the
expression of Apaf-1, procaspases-2, -3, -6, -7, -8, -10, and PARP
in diagnostic samples containing at least 85% leukemic blasts of 43
children with ALL and 10 children with AML using quantitative
Western blotting. The protein expression was compared between
B-lineage ALL, T-lineage ALL, and AML, and between acute
leukemia cases that are in vitro–sensitive and resistant to pred-
nisolone (PRED; Bufa Pharmaceutical Products, Uitgeest, The
Netherlands), vincristine (VCR; TEVA Pharma, Mijdrecht, The
Netherlands), L-asparaginase (ASP; Paronal; Christiaens, Breda,
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The Netherlands), and daunorubicin (DNR; Cerubidine; Rhoˆne-
Poulenc Rorer, Amstelveen, The Netherlands).
Patients, materials, and methods
Leukemia samples
Bone marrow and peripheral blood samples were obtained at initial
diagnosis after informed consent from children with newly diagnosed ALL
who were enrolled on protocol Dutch Childhood Oncology Group (DCOG)
ALL-9 at the Erasmus MC/Sophia Children’s Hospital or on COALL-97
treatment protocol at one of the hospitals participating in the German
COALL study group. Approval was obtained from the Erasmus MC/Sophia
Children’s Hospital institutional review board for these studies. Mono-
nuclear cells were isolated by sucrose density gradient centrifugation
(Lymphoprep, density 1.077 g/mL; Nycomed Pharma, Oslo, Norway),
within 24 hours after sampling at the research laboratory of Pediatric
Oncology, Erasmus MC/Sophia Children’s Hospital, Rotterdam, The Neth-
erlands. Cells were resuspended in culture medium consisting of RPMI
1640 (Dutch modification without L-glutamine; Gibco BRL, Life Technolo-
gies, Breda, The Netherlands) supplemented with 20% fetal calf serum
(FCS; Integro, Zaandam, the Netherlands), 2 mM L-glutamine, 200 g/mL
gentamycin (Gibco BRL) 100 IU/mL penicillin, 100 g/mL streptomycin,
0.125 g/mL fungizone (Gibco BRL), and 5 g/mL insulin, 5 g/mL
transferring, and 5 ng/mL sodium selenite (bovine insulin, human trans-
ferin, and sodium selenite [ITS] media supplement; Sigma-Aldrich Chemie
B.V., Zwijndrecht, the Netherlands). If necessary, leukemic samples were
further enriched to at least 85% leukemic blasts by removing nonmalignant
cells with immunomagnetic beads (DynaBeads, Dynal Oslo, Norway).23
Cell pellets were immediately stored at80°C until use.
Antibodies
Monoclonal mouse antibodies to human procaspase-2 or PARP were
purchased from PharMingen (San Diego, CA). Polyclonal rabbit antibodies
to human procaspase-6, procaspase-10, and a monoclonal mouse antibody
to human procaspase-8 were purchased from Cell Signaling Technology
(Beverly, MA). In addition, we used monoclonal mouse antibodies to
human procaspase-3 (Transduction Laboratories, Lexington, KY) and
procaspase-7 (StressGen, Victoria, BC, Canada). Monoclonal antibodies
tested for human procaspase-9 were purchased at Oncogene Research
Products (Cambridge, MA), Santa Cruz Biotechnology (Santa Cruz, CA)
and Cell Signaling Technology.
In vitro drug resistance assay
Responsiveness of leukemia cells to PRED, VCR, ASP, and DNR was
determined by the 4-day in vitro (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide) MTT drug resistance assay as described
previously.3,4 The concentration ranges tested for these drugs were as
follows: PRED, 0.008-250 g/mL; VCR, 0.05-50 g/mL; ASP, 0.003-10
IU/mL; and DNR, 0.002-2.0 g/mL. The drug concentration lethal to 50%
of the ALL cells (LC50 value) was used as the measure of cellular drug
resistance. The PRED, VCR, and ASP (PVA) score was calculated as
previously described (ie, each patient was given a score according to the
LC50 value measured in the MTT assay).4 Patients were given a score of 1 if
sensitive, 2 if intermediate, and 3 if resistant per agent. (The cut-off LC50
values used to assign these scores were those previously associated with
treatment outcome in ALL4,24 and are provided in Table 1). The sum of the
individual scores for PRED, VCR, and ASP resulted in the PVA score.
Patients with a combined PVA score of 3 or 4 are relatively sensitive to
PRED, VCR, and ASP, and have a favorable treatment outcome compared
with patients with a combined PVA score of 7, 8, or 9, which are relatively
resistant to these 3 drugs.
Western blotting
Leukemic cells were lysed in 50 mM Tris (tris(hydroxymethyl)-
aminomethane; pH 7.6) containing 150 mM NaCl, 10 mM EDTA (ethyl-
enediaminetetraacetic acid), and 1% Triton X-100. Protease inhibitors (200
g/mL pepstatin A, 200 g/mL leupeptin and 2 mM PMSF [phenylmethyl-
sulfonyl fluoride]) were freshly added prior to use. Protein concentration
was determined using the bicinchoninic acid (BCA) protein assay (Pierce,
Rockford, IL). All samples were kept on ice during the protein isolation and
lysates were either used directly or stored immediately at 80°C until use.
Twenty micrograms of protein in Laemmli buffer (4% [wt/vol] sodium
dodecyl sulfate [SDS], 100 mM Tris-HCl [pH 6.8], and 20% glycerol) was
heated to 100°C for 3 minutes and loaded onto a 5% to 15% gradient
polyacrylamide gel. After electrophoresis, samples were transferred to
nitrocellulose blots, blocked with skim milk, and incubated for 1 hour with
primary antibodies. Blots were washed and incubated for 1 hour with
peroxidase-conjugated secondary antibody (DAKO, Carpentaria, CA).
Presence of proteins was detected by enhanced chemiluminescent staining
using the SuperSignal West Femto kit (Pierce). Signals were directly
scanned by the ChemiGenius imaging system (SynGene, Cambridge,
United Kingdom) and signal intensity was quantified using GeneTools 3.1
image analysis software (SynGene).
Quantification of apoptotic proteins
A dilution series of 30, 25, 20, 15, and 10 g protein lysate of the human
B-cell leukemia cell line Reh (N CRL-8286; ATCC, Rockville, MD) was
included in each gel. Expression levels of protein were expressed in
arbitrary units (AU) and were based on the relative quantity present in the
patient’s sample compared to the Reh cell line dilution series (Figure 1).
Reproducibility of our method was assessed by subjecting 27 samples to
duplicate Western blot analysis and is illustrated in Figure 2 for 16
representative samples.
Table 1. Cut-off LC50 values used to assign a patient as in vitro
sensitive, intermediate, or resistant per drug
Drug In vitro sensitive In vitro resistant
PRED, g/mL  0.100  150
VCR, g/mL  0.391  1.758
ASP, IU/mL  0.033  0.912
DNR, g/mL  0.075  0.114
Figure 1. Quantification of apoptotic proteins in newly diagnosed childhood
acute leukemia. A representative blot for cells of 9 acute leukemia samples
incubated with monoclonal anti-PARP antibody is depicted in the top panel. The
dilution series consists of 30, 25, 20, 15, and 10 g Reh protein lysate. The presence
of PARP was detected by enhanced chemiluminescent staining and the signal
intensity was quantified by densitometry and plotted (bottom). This graph was used to
estimate the relative quantity present in the patient’s sample compared with the Reh
cell line dilution series by linear regression. The 9 samples shown here are part of the
group of 53 patients and include 3 B-lineage ALL samples, 3 T-lineage ALL samples,
and 3 AML samples. OD indicates optical density.
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Real time quantitative PCR
Total cellular mRNA was extracted using Trizol reagent (Gibco BRL) and
cDNA was synthesized using random hexamers and oligo dT primers.
mRNA expression levels of PARP and GAPDH as a reference, were
quantified using real-time polymerase chain reaction (PCR) analysis on an
ABI Prism 7700 sequence detection system (Applied Biosystems, Foster
City, CA) as previously described.25 PCR reactions were performed and
optimized to an amplification efficiency of more than 95%. The compara-
tive cycle time (Ct) value of the target PCR was normalized by subtracting
the Ct value of GAPDH (Ct). The Ct value was used to calculate the
relative expression level to GAPDH for each target PCR using the following
formula: relative mRNA expression  2-Ct  100%.25 PARP primer
sequences used were: sense, 5-AGGCTGCTTTGTCAAGAA-3; and
antisense, 5-CTTGCTGCTTGTTGAAGAT-3 and the probe sequence:
5-ATGAGGTGGATGGAGTGGATGA-3. GAPDH primers and probe
sequences have been described elsewhere.26
Fluorescence in situ hybridization analysis
To investigate the PARP gene copy number, dual colored fluorescence in
situ hybridization (FISH) was applied using 2 combinations of probes:
(1) Two 1q42-specific bacterial artificial chromosome (BAC) clones
(Roswell Park Cancer Institute, Buffalo, NY), RP11-118H4 labeled with
biotin-16–deoxyuridine triphosphate (dUTP), and RP11-125A15 la-
beled with digoxigenin-12–dUTP, with a 50-kilobase (kb) overlap in the
PARP gene; and (2) a combination of the PARP-specific BAC clone
RP11-118H4 (labeled with biotin-16–dUTP) and 2 P1-derived artificial
chromosome (PAC) clones 203H23 and 213H16 (RCPI-6 Human PAC
Library, Roswell Park Cancer Institute) labeled with digoxigenin-12–
dUTP specific for the AF1q gene on 1q21. Cytospins of leukemic
samples stored at 20°C were used for FISH analysis. The FISH
protocol was based on that described previously.27 Briefly, slides were
pretreated with RNase and pepsin and subsequently fixed with formalde-
hyde. Hybridization of 100 ng of each probe to the slides was performed
overnight at 37°C. Biotinylated probes were detected via subsequent
incubation with fluorescein isothiocyanate (FITC)–labeled avidin-d,
biotinylated goat–anti-avidin and avidin-d FITC (Vector, Burlingame,
CA), whereas digoxigenin-labeled probes were detected via sheep–anti-
digoxigenin tetramethylrhodamine isothiocyanate (TRITC)–labeled an-
tibodies (Boehringer Mannheim, Mannheim, Germany), followed by
Texas-red–conjugated donkey antisheep antibodies (Jackson ImmunoRe-
search, Westgrove, PA). Slides were counterstained with DAPI (4,6-
diamidino-2-phenylindole) and embedded in Vectashield (Vector Labo-
ratories, Burlingame, CA)/DABCO (1,4-diazabicyclo[2,2,2]octane).
Hybridization results were examined using a Zeiss Axioplan 2 fluores-
cence microscope (Zeiss, Oberkochen, Germany).
Statistics
Protein expression in different leukemic subgroups (B-lineage ALL,
T-lineage ALL, and AML) was compared using the Mann-Whitney U test.
Spearman rank (rs) correlation test was used to correlate protein expression
to several variables on the study. Statistical tests were performed at a
2-tailed significance level of .05. Whenever applicable, a Bonferroni
correction was applied to correct for multiple comparisons.
Results
Expression of various apoptotic proteins in ALL
The expression of Apaf-1, procaspases-2, -3, -6, -7, -8, -10, and
PARP was first determined in a test group of 20 children with ALL.
These 20 patients were selected by having a PVA score of 3 or 4 (ie,
relatively in vitro–sensitive to PRED, VCR, and ASP; n  10) or 7,
8, or 9 (ie, relatively in vitro–resistant to PRED, VCR, and ASP;
n  10). The expression of procaspase-9 could not be analyzed in
these samples since all procaspase-9 antibodies tested revealed
abundant nonspecific staining, whereas staining of procaspase-9
itself was low. Most other apoptotic proteins were ubiquitously
expressed in the ALL samples and varied markedly between
patients (Figure 3). Exceptions were procaspase-10 and PARP,
which were not expressed in 4 (2 B-lineage ALL, 2 T-lineage ALL)
and 1 (T-lineage ALL) out of the tested 20 samples, respectively.
Expression values in arbitrary units (AU) for each apoptotic protein
are provided in Table 2. The variation in expression ranged
Figure 2. Reproducibility of PARP and procaspase-2 protein detection in
childhood acute leukemia samples. Representative Western blots from 2 indepen-
dent experiments incubated with monoclonal anti-PARP or anti–procaspase-2
antibodies are depicted.
Figure 3. Variation in expression of 8 apoptotic proteins in PRED, VCR, and
ASP (PVA)–sensitive and –resistant childhood ALL. Protein levels of Apaf-1,
procaspases-2, -3, -6, -7, -8, -10, and PARP of leukemic cells from 10 patients
compared by Western blot analysis. Arrows indicate the positions of full-length
procaspase-2 (48 kDa), procaspase-3 (32 kDa), procaspase-6 (33 kDa), pro-
caspase-7 (35 kDa), procaspase-8 (50/55 kDa), procaspase-10 (58 kDa), full-length
and cleaved PARP (116/89 kDa), and Apaf-1 (140 kDa). The in vitro drug responsive-
ness of each patient is indicated below each lane; R indicates in vitro resistant and S
indicates in vitro sensitive toward PRED, VCR, and ASP (PVA), as explained in
“Materials and methods.”
Table 2. Apoptosis-associated protein expression in PRED, VCR,









Apaf-1 21.6 (12.7-124.4) 17.4 (4.0-175.3) .529
Procaspase-2 13.4 (1.1-27.2) 6.2 (1.2-10.1) .019
Procaspase-3 18.5 (9.9-41.0) 20.8 (8.0-35.7) .912
Procaspase-6 17.5 (11.0-78.8) 25.2 (16.3-49.0) .280
Procaspase-7 10.8 (6.1-32.4) 8.6 (1.0-25.2) .247
Procaspase-8 32.4 (21.5-75.2) 42.3 (17.0-110.1) .393
Procaspase-10 5.4 (0.0-40.8) 6.4 (0.0-47.0) .912
PARP 35.8 (6.5-48.9) 15.1 (0.0-38.5) .042
Expression of 8 apoptotic proteins was compared in 10 PVA-sensitive (8
B-lineage ALL, 2 T-lineage ALL) and 10 PVA-resistant (5 B-lineage, 5 T-lineage)
patients. For both groups, n  10.
*The expression of the predominantly expressed isoform was examined for all
proteins.
†Expression of an apoptotic protein in patient samples related to the expression
of protein in a dilution series of the Reh leukemic cell line; see “Materials and
methods.”
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between 5-fold for procaspase-3 and 44-fold for Apaf-1. In vitro
cross-resistance to PVA is an important independent predictor of
treatment failure and long-term outcome in childhood ALL.4,5,28
Therefore, the expression of the 8 apoptotic proteins was subse-
quently correlated to in vitro PVA resistance. Only procaspase-2
and PARP protein expression were significantly associated with in
vitro PVA resistance in ALL. Procaspase-2 expression was 2.2-fold
lower in cells of ALL patients resistant to PRED, VCR, and ASP,
hereafter called PVA resistant (median: 6.2 AU) compared with
cells of ALL patients sensitive to these 3 drugs, hereafter called
PVA sensitive (median, 13.4 AU; P  .019). PARP expression was
2.4-fold lower in PVA-resistant (median, 15.1 AU) compared with
PVA-sensitive children with ALL (median, 35.8 AU; P  .042).
Based on these data, we examined the expression of PARP and
procaspase-2 in a larger group of children with ALL (n  43) and
AML (n  10).
Expression of PARP in acute leukemia
Twenty-eight patients with B-lineage ALL, 15 patients with
T-lineage ALL, and 10 patients with AML were studied. PARP
expression varied between 0 and 59.8 AU in these patients with the
relatively highest expression level found in B-lineage ALL (Figure
4A). The expression of PARP was significantly lower in T-lineage
ALL (median, 4.3 AU; P  .001) and in AML (median, 3.1 AU;
P  .001) compared to B-lineage ALL (median, 32.0 AU). PARP
expression did not differ significantly between AML and T-lineage
ALL. Whereas all patients with B-lineage ALL showed PARP
expression, we identified 4 T-ALL and 3 AML patients without
detectable PARP expression. PARP mRNA levels correlated with
PARP protein levels (rs  .58, P  .018). FISH analysis of the 4
patients with T-lineage ALL and 3 patients with AML with absent
PARP protein expression revealed that the lack of PARP protein
and mRNA expression was not associated with genomic dele-
tions in the PARP gene region of these patients (data not shown).
Epigenetic changes such as DNA methylation of promoter regions may
result in decreased mRNA levels; however, no cytosine-phosphate-
guanine (CpG) islands have been reported within the promoter region of
PARP, nor could we identify these using the CpGPlot program
(http://www.ebi.ac.uk/emboss/cpgplot/).29
Next, we compared PARP expression in sensitive and resistant
patients with acute leukemia to PRED, VCR, ASP, or DNR. After
correction for multiple comparisons (Bonferroni model), we ob-
served a significantly decreased PARP expression in samples
resistant to PRED, VCR, and ASP (Table 3). PVA resistance data
were available for 8 AML samples, 15 T-lineage ALL samples, and
28 B-lineage ALL samples; of these, 5 AML samples (63%) and 12
T-lineage ALL samples (80%) were PVA resistant, whereas only 10
B-lineage ALL samples (36%) were PVA resistant. This is in line
with our previous findings that children with AML and T-lineage
ALL are relatively in vitro–resistant to various drugs including
PRED, VCR, and ASP.7,30 Since PRED, VCR, and ASP are an
integral part of ALL therapy, PARP expression was compared
between PVA-sensitive and PVA-resistant ALL samples. Within
the total group of ALL cases, PVA-resistant cases (median, 39.2
AU) had a 4-fold lower expression of PARP compared with
sensitive cases (median, 9.2 AU, P  .001). Our observation that
PARP expression is lower in T-ALL and that this immunopheno-
type is associated with cellular drug resistance partly explains our
finding that low PARP expression is associated with PVA resistance
in pediatric ALL (Figure 4B). Within the B-lineage group, PVA-
resistant patients (n  10; median, 20.2 AU) also had a 2-fold
lower expression of PARP compared with sensitive patients
(n  18, median, 39.8, P  .040; Figure 4B, open symbols). No
difference was found in PARP expression between ALL patients
with an M1 bone marrow response at day 15 and those having an
M2 or M3 bone marrow response (P  .11). Due to limited
follow-up of patients no relevant comparisons with long-term
outcome could be made.
Expression of procaspase-2 in acute leukemia
A slightly smaller group of 34 ALL cases (besides 10 AML) were
analyzed for procaspase-2 expression due to limitations in availabil-
ity of material. Procaspase-2 expression was detectable in all
leukemic samples. As shown in Figure 5A, procaspase-2 expres-
sion varied between 2.1 and 65.4 AU in these patients, with the
relatively highest expression level found in B-lineage ALL. The
Figure 4. PARP expression levels in different types of childhood acute
leukemia and in drug-resistant versus -sensitive childhood ALL. (A) PARP
expression in different types of childhood acute leukemia. Each dot represents an
individual patient and the horizontal bar represents the median protein level. Protein
expression level of PARP was quantitated in 28 B-lineage ALL samples (E), 15
T-lineage ALL samples (F) and 10 AML samples (). (B) PARP expression versus in
vitro PRED, VCR, and ASP (PVA) resistance in childhood acute lymphoblastic
leukemia. The protein expression level of PARP quantitated in 21 PVA-sensitive (S)
and 22 PVA-resistant (R) patients with B-lineage ALL (E) or T-lineage ALL (F).
*Statistically significant after Bonferroni correction for multiple comparisons. AU
indicates arbitrary units.
Table 3. PARP and procaspase-2 expression in childhood acute leukemia patients sensitive and resistant to PRED, VCR, ASP, and DNR
PARP Procaspase-2
No. studied Median, AU P No. studied Median, AU P
PRED sensitive 20 39.8  .001* 15 24.7 .012*
PRED resistant 21 6.9 19 8.8
VCR sensitive 24 31.0 .002* 19 22.0 .142
VCR resistant 21 4.7 18 9.3
ASP sensitive 21 31.7 .004* 18 23.3 .070
ASP resistant 22 7.0 19 9.5
DNR sensitive 30 31.0 .017 24 12.8 .188
DNR resistant 9 4.7 8 7.3
*Statistically significant after Bonferroni correction for multiple comparisons.
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expression of procaspase-2 was 3-fold lower in T-lineage ALL
(median, 7.0 AU; P  .014) and in AML (median, 6.80; P  .022)
compared with B-lineage ALL (median, 22.0 AU). Procaspase-2
expression did not differ significantly between AML and T-lineage
ALL (P  .976).
Procaspase-2 expression was compared between in vitro–
sensitive and –resistant patients for PRED, VCR, ASP, or DNR as
single drugs. After correction for multiple comparisons, we ob-
served that decreased procaspase-2 expression was related to in
vitro PRED resistance only, although a trend with resistance to the
other drugs was found (Table 3). Within the total group of ALL
patients, PVA-resistant cases (median, 9.7 AU) had a 2-fold lower
expression of procaspase-2 compared with sensitive cases (median,
24.0 AU, P  .042; Figure 5B). Within the B-lineage group,
PVA-resistant patients (n  6; median, 11.8 AU) had a 2.1-fold
lower expression of procaspase-2 compared with sensitive patients,
although this difference was not statistically significant (n  15,
median, 24.7 AU, P  .132; Figure 5B, open symbols).
Since the expression of procaspase-2 and PARP showed similar
expression patterns, we examined the possibility whether the
expression of both proteins was correlated. As shown in Figure 6
there is a strong positive correlation between the expression of
PARP and procaspase-2 (rs  .58, P  .001). Procaspase-2 expres-
sion did not differ between ALL patients with an M1 bone marrow
response at day 15 and those having an M2 or M3 bone marrow
response (P  .30). Due to limited follow-up of patients no
relevant comparisons with long-term outcome could be made.
Discussion
The prognosis of childhood acute lymphoblastic leukemia (ALL)
has improved remarkably over the past 4 decades due to the
introduction of effective combination risk-adapted therapies. Con-
ventional factors used to stratify patients are clinical and biological
parameters such as age and white blood cell (WBC) count at
diagnosis, immunophenotype, the presence of specific genetic
abnormalities,1 and initial response to PRED treatment.31 Newer
approaches are measurement of minimal residual disease after
induction of initial remission32 and in vitro drug resistance
profiles.4 We and others showed that children whose leukemic cells
exhibit in vitro resistance to antileukemic agents, especially to
PRED, VCR, and ASP, have a significantly worse prognosis than
patients whose ALL cells are sensitive.3-6 Children with T-lineage
ALL and AML are, in vitro, more resistant to a variety of drugs.7,30
The use of more intensive risk-adapted treatment regiments,
however, has resulted in a prognosis for children with T-lineage
ALL similar to that of children with B-lineage ALL.33 In the
present study, the expression of Apaf-1, procaspases-2, -3, -6, -7,
-8, -10, and PARP was studied in childhood ALL and AML and was
related to immunophenotype and in vitro resistance to PRED,
VCR, and ASP (PVA) as well as to resistance to PRED, VCR, and
ASP and DNR individually.
We observed no relation between the expression of Apaf-1,
procaspases-3, -6, -7, -8, and -10, and PVA resistance in childhood
ALL in the present study. The absence of a relation with drug
resistance may explain why no prognostic value was found for
these proteins in adult ALL and AML,22 although data in children
and adults are not necessarily interchangeable. In a previous study
we demonstrated that the degree of caspase-3 activation (ie,
cleavage of procaspase-3 into caspase-3) correlates with the degree
of resistance to PRED and ASP in childhood ALL.17 In our present
study no correlation was found between the baseline expression
levels of procaspase-3 and resistance to these chemotherapeutic
drugs. Taken together, these studies suggest that resistance to these
2 drugs may not be caused by decreased availability of the active
enzyme due to decreased expression of procaspase-3, but rather
may be caused by defects upstream of caspase-3 that inhibit
caspase-3 activation upon PRED or ASP exposure.
PARP (Enzyme Commission [EC] 2.4.2.30) is an abundantly
expressed nuclear enzyme, which binds to single- or double-
stranded DNA breaks in response to DNA damage. At the breakage
site, PARP catalyzes the transfer of the ADP-ribose polymers from
the respiratory coenzyme NAD to nuclear acceptor proteins
involved in chromatin structure, DNA repair, and DNA metabo-
lism.34 Its poly(ADP-ribosylation) activity as well as its association
with components of base-excision repair35 contribute to the role of
PARP in DNA repair and the maintenance of genomic integrity. In
the present study, we observed that in vitro drug-resistant child-
hood leukemia subtypes (ie, T-lineage ALL and AML), have a
decreased and occasionally even absent expression of PARP.
Complete absence of PARP expression was observed in 4 out of 15
patients with T-lineage ALL and 3 out of 10 patients with AML, but
in none of the patients with B-lineage ALL. The variation in PARP
expression between leukemia subtypes suggests that caution should
be taken when interpreting studies that examining protein expres-
sion in a mixed group of B-lineage ALL, T-lineage ALL, and AML
samples without correcting for leukemia subtypes. The absence of
PARP was not caused by deletions of the PARP gene. Given the
absence of CpG islands within the PARP promoter, it seems
Figure 6. Correlation between PARP and procaspase-2 protein levels in newly
diagnosed childhood acute leukemia. Comparison between PARP and pro-
caspase-2 protein expression levels in 21 B-lineage ALL samples (E), 13 T-lineage
ALL samples (F), and 10 AML samples (). Diagonal line indicates line of best fit.
Figure 5. Procaspase-2 expression levels in different types of childhood acute
leukemia and in drug-resistant versus -sensitive childhood ALL. (A) Pro-
caspase-2 expression in different types of childhood acute leukemia. Each dot
represents an individual patient and the horizontal bar represents the median protein
level. Protein expression level of procaspase-2 quantitated in 21 B-lineage ALL
samples (E), 13 T-lineage ALL samples (F), and 10 AML samples (). (B)
Procaspase-2 expression versus in vitro PRED, VCR, and ASP (PVA) resistance in
childhood acute lymphoblastic leukemia. The protein expression level of PARP
quantitated in 16 PVA-sensitive (S) and 18 PVA-resistant (R) patients with B-lineage
ALL (E) or T-lineage ALL (F). *Statistically significant after Bonferroni correction for
multiple comparisons.
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unlikely that the absence of PARP is caused by methylation-
induced PARP silencing in these patients. The presence of putative
binding sites for several transcription factors, including simian
virus 40 protein 1 (Sp-1),36,37 activator protein-2 (AP-2),37 v-ets
erythroblastosis virus E26 oncogene homolog 1 (Ets-1),38 and
yin-yang 1 (YY1)39 within the PARP promoter region, suggests that
PARP expression is regulated at the transcriptional level. In
addition, we observed that decreased or absent expression of intact
PARP is related to in vitro resistance to PRED, VCR, and ASP in
childhood ALL. Other studies also reported that depletion of PARP,
either by gene disruption,40,41 antisense RNA,40,42 or pharmacologic
inhibitors,40,43-45 resulted in decreased drug-induced apoptosis.
Various explanations have been proposed for the requirement of
PARP during apoptosis, including depletion of cellular nicotinamide-
adenine nucleotide (NAD) and adenosine triphosphate (ATP)
pools,46 modification of proteins involved in apoptosis like p53,47,48
facilitation of oligonucleosomal DNA fragmentation,49 and up-
regulation of P-glycoprotein in PARP-depleted cells.41 We previ-
ously observed that resistance to PRED and ASP, but not to VCR
and DNR, is linked to decreased drug-induced PARP cleavage (ie
inactivation of PARP).17 Our current observation that resistant cells
express lower baseline levels of this protein suggests that the
suitability to use cleaved PARP as read-out for functional apoptosis
is drug/stimuli dependent.
Caspase-2 activity is implicated in the initiation50,51 as well as
the effector phase52,53 of apoptosis induced by various stimuli. The
present study shows a decreased procaspase-2 expression in in
vitro drug-resistant childhood leukemia subtypes (ie, T-ALL and
AML). In addition, we observed a relation between decreased
procaspase-2 expression and in vitro PVA resistance in childhood
ALL. This suggests that sufficient intracellular amounts of pro-
caspase-2 are required to respond to these drugs, and that relative
deficits in procaspase-2 expression levels may contribute to cellular
PVA resistance in childhood acute leukemia. In adult acute
leukemia, high expression of procaspase-2 was not linked to
prognosis.19-22 The lack of prognostic value for the response to
combination chemotherapy in these studies does not rule out a role
for procaspase-2 in cellular responses to PRED and/or other drugs
in adult leukemias. Since this relationship has not been addressed
in adults so far, no comparison between childhood and adult studies
can be made. In cell lines the requirement of caspase-2 for
drug-induced apoptosis was shown to be highly cell specific.51,54,55
Decreased PARP and procaspase-2 expression did correlate
with in vitro PVA resistance, whereas these expression levels did
not correlate with an early bone marrow response at day 15. One
may argue that this is exactly the time period when the leukemia is
treated with PRED, VCR, and ASP in most protocols. However, in
the COALL-97 protocol, patients are first treated with a DNR
window (up-front combination chemotherapy) for 7 days, followed
by PRED, VCR, and DNR for 4 weeks. After this period of 5 weeks,
ASP is given for the first time. Since PARP and procaspase-2 expression
are not linked to DNR resistance, and this drug is used up-front of
combination chemotherapy as well as in the first 4 weeks, this may
explain the lack of correlation between both proteins and day-15 bone
marrow response of COALL-97 patients.
In our previous study we observed that resistance to each of the
4 studied drugs (PRED, VCR, ASP, and DNR) was associated with
a decreased ability to expose phosphatidyl serine on the outer
membrane and decreased collapse of the mitochondrial membrane
potential.17 Caspase-3 activation and PARP inactivation correlated
to PRED and ASP resistance, but not to VCR and DNR resistance.
This finding suggested that cleaved caspase-3 and PARP are not
important determinants of the VCR- and DNR-triggered apoptotic
route. Both phosphatidyl serine exposure and the collapse of the
mitochondrial membrane potential occurred earlier than caspase-3
activation and PARP inactivation, implying that resistance to these
4 drugs is caused by a blockade at the level of or upstream of
mitochondrial function. The identity of these upstream causes of
resistance are part of extensive research in the past few years by
different groups (reviewed by Pieters and Den Boer56).
Recently, new insights were obtained by comparing gene
expression profiles of drug-resistant and -sensitive cells of children
with ALL.24 In this latter study, drug-specific genes rather than
more general apoptosis-associated genes (such as caspases, Bcl-2
family members, and inhibitors of apoptosis [IAP] factors) were
among the most discriminative genes that were associated with
resistance to PRED, VCR, ASP, and DNR in ALL cells. These
findings do not rule out a role for altered expression and/or activity
of apoptosis genes, but suggest that, at the mRNA level, genes
upstream of the apoptosis-execution pathway are more important
for resistance to these drugs. At the protein level, we here show that
the basal expression levels of Apaf-1 and procaspase-3, -6, -7, -8,
and -10 are not differentially expressed between drug-resistant and
-sensitive patients with acute leukemia. Expression of procaspase-2
and PARP were decreased in children with drug-resistant ALL. The
causal aspect of this association should be further determined with
functional studies showing the sensitizing effect of ectopic expres-
sion of PARP and procaspase-2 on drug resistance in leukemic cells
of children with ALL.
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